Background: Perioperative mortality is low for patients undergoing abdominal aortic aneurysm (AAA) repair, but long-term survival remains poor. Although patients diagnosed with AAA have a significant burden of cardiovascular disease and associated risk factors, there is limited understanding of the contribution of cardiovascular risk management to long-term survival. 
Introduction
Since the advent of endovascular technology and improvements to the provision of vascular services, perioperative mortality has declined for patients undergoing abdominal aortic aneurysm (AAA) repair in England, from 7⋅9 per cent 1 to 1⋅8 per cent 2 between 2006 and 2014. Despite these advances, the longer-term outlook for patients with an AAA is poor, and life expectancy after AAA repair remains significantly worse than for equivalent individuals without an AAA 3, 4 . In part, this excess risk is due to the greater burden of both clinical and subclinical cardiovascular disease (CVD) and associated risk factors in patients with an AAA, including a 2⋅78-fold increase in ischaemic heart disease (IHD) and a 2⋅2-fold increase in cerebrovascular disease 5 .
These findings explain the observation that patients with an AAA have twice the rate (1⋅4 versus 2⋅8 per cent per year) of adverse cardiovascular events (including death from CVD, non-fatal myocardial infarction and non-fatal stroke) compared with patients without an AAA 5 . Patients with an AAA should receive evidence-based treatments that reduce CVD risk, analogous to the secondary prevention of coronary heart disease (CHD). In the UK and elsewhere, nearly 100 per cent of patients who survive a myocardial infarction are discharged on aspirin, a P2Y12 inhibitor, a statin, a beta-blocker and an angiotensin-converting enzyme (ACE) inhibitor (if there is no contraindication). It is believed that a large proportion of the reduction in CHD deaths in the UK can be attributed to this regimen. In contrast, small local series suggest that as few as 40 per cent of patients with AAA receive statin therapy 6 . 1 Directed acyclic graph for description of hypothesized or known causal links between variables used in the study. SHA, Strategic Health Authority; CAN, cancer; MET, metastatic tumour; REN, renal disease; AF, atrial fibrillation; DM, diabetes mellitus; PAD, peripheral arterial disease; CCF, congestive cardiac failure; PUD, peptic ulcer disease; IHD, ischaemic heart disease; MI, myocardial infarction; MIL, mild inflammation of the liver; MLD, moderate liver disease; CD, cerebrovascular disease; HEM, hemiplegia; RHE, rheumatological disease; CPD, chronic pulmonary disease Although statins 7 , antiplatelet agents 8 and antihypertensive treatments 9 have a well established evidence base for reducing cardiovascular risk among patients with clinically manifest coronary disease, there are no comparable data among patients with an AAA. Nevertheless, consensus guidelines for AAA recommend the importance of medications known to reduce CVD risk in this group 10 . Here, the goal was to provide real-world observational data among patients with an AAA regarding the use of medications known to reduce CVD risk, and to assess whether there is an association between their prescription and long-term survival. This was done by applying the G-computation formula, a technique that adjusts for potential confounding between time-varying treatments and time-varying co-variables 11 .
Methods
General practice records within The Health Improvement Network (THIN) database were examined. Patients with a recorded diagnosis of AAA were identified from 2000 to 2012 with at least 1 year of registered medical history before the diagnosis. The inclusion criteria required information regarding a known deprivation index and smoking status, and a minimum age of 50 years, to exclude those with non-degenerative aortic pathology. Data were extracted regarding patients' prescription medications, demographics, co-morbidity, smoking status and social deprivation index.
The primary outcome was 5-year survival, defined from the first recorded diagnosis of AAA. Co-morbidity was characterized according to a validated classification system for THIN data, and each diagnosis was extracted when first recorded in a patient's record 12 . Medical therapies known to reduce cardiovascular risk were classified as antiplatelet or anticoagulation agents, statins and lipid-modifying therapy (LMT) or antihypertensive agents. Separate consideration was given to the most common antiplatelet drugs, aspirin, clopidogrel and dipyridamole, and the grouped analysis included newer agents such as prasugrel and ticagrelor. Anticoagulants included heparin and its derivatives, warfarin and newer oral anticoagulants. 
Statistical analysis
The demographic characteristics of the overall cohort are reported using descriptive statistics, with further subclassification into those with an additional history of CHD, cerebrovascular disease, peripheral arterial disease (PAD) and diabetes mellitus (DM). This was done to assess whether concomitant vascular disease or DM was associated with different medical prescribing than that in patients with AAA but no other prevalent vascular disease. The χ 2 test or Mann-Whitney U test was used to compare the rate of prescription for each category of medical therapy (antiplatelet agent, statins, antihypertensive agents). Adjusted survival curves were constructed using inverse probability weights 13 with, and without each category of medical therapy (antiplatelet agent, statins, antihypertensive agents), taking into account the time dependency of the treatments 14 , to represent the univariable impact of each medical therapy on 5-year survival graphically.
Multivariable analysis was performed by applying the G-computation formula, a technique developed under the causal inference framework to adjust for potential confounding between time-varying treatments and time-varying co-variables, where both are related to the outcome of interest 11 . A directed acyclic graph (DAG) was constructed to describe the potential causal relations between the variables of the study 15, 16 (Fig. 1) . The DAG was used to fit pooled logistic regression models with time introduced by splines or non-linear terms. Models were fitted for each time-dependent co-morbidity, AAA surgery, each drug category and death. Co-morbidities, AAA surgery and death were modelled as time to the first event recorded, and baseline demographics and deprivation index were included in all models.
The G-formula approach was used to compare hypothetical drug interventions (scenarios) by simulating patient cohorts, modelled as described above. Survival comparisons were performed between a scenario in which all patients received the medical therapy of interest (statin, antiplatelet agent, antihypertensive agent or anticoagulant) versus a scenario in which no patient received that therapy (all versus none). Comparison was also made between a scenario in which all patients received drug therapy compared with one in which the proportion receiving therapy matched that in current practice (all versus current practice). Finally, current practice was compared with a scenario in which no patient received the therapy of interest (current practice versus none). The data were split into 4-week intervals for computational purposes after conducting sensitivity analyses, using 1-week intervals in some scenarios. When a treatment was prescribed, it was assumed to last for the next 90 days (an approach commonly taken for THIN data 17 ), and co-morbidities (apart from smoking) were regarded as irreversible once acquired.
As a sensitivity analysis, effect estimates were also obtained for each medical therapy using a traditional Cox proportional hazards model with time-dependent co-variables to assess the potential for observational confounding in non-causal analysis of these epidemiological data. All analyses were performed using SAS ® version 9.3 (SAS Institute, Cary, North Carolina, USA).
Results
Between January 2000 and December 2012 there were 12 485 patients with a recorded diagnosis of AAA who formed the cohort for this study; they had been registered in their health centre before AAA diagnosis for a mean(s.d.) of 21⋅7(16⋅7) years. The majority of patients were men (74⋅8 per cent), with a mean(s.d.) age of 73⋅9(8⋅5) years. AAA, abdominal aortic aneurysm; IHD, ischaemic heart disease; CD, cerebrovascular disease; DM, diabetes mellitus; PAD, peripheral arterial disease; LMT, lipid-modifying therapy. *P < 0⋅001 versus no co-morbidity (Mann-Whitney U test); †P < 0⋅001 versus no co-morbidity (χ 2 test).
Unsurprisingly many had a history of other vascular diseases such as IHD (32⋅0 per cent), myocardial infarction (18⋅2 per cent), cerebrovascular disease (16⋅6 per cent) and PAD (24⋅3 per cent), although 43⋅0 per cent had no history of disease in any other vascular bed (Table S1 , supporting information). The use of all major classes of cardioprotective medication was low (26⋅6 per cent for statins, 75⋅3 per cent for antihypertensives and 56⋅5 per cent for antiplatelets) in 2000, but increased over the decade: by 2012, 76⋅7 per cent of patients were receiving a statin, 84⋅0 per cent were receiving an antihypertensive agent and 73⋅9 per cent were prescribed an antiplatelet agent within 1 year of AAA diagnosis (Fig. 2) . Use of these medications was considerably higher when AAA was accompanied by IHD, DM, PAD or cerebrovascular disease than in patients with an AAA but no vascular co-morbidity (P < 0⋅001 for all comparisons) ( Table 1) .
There were considerable geographical variation in prescription rates between different SHAs for statins and antiplatelet agents, but not for antihypertensive medications (Fig. S1, supporting information) . The rate of prescription of antiplatelet agents varied by 5 per cent between SHAs, whereas that for statins varied by nearly 10 per cent.
Adjusted survival and medication for cardiovascular risk
Within 5 years after a new diagnosis of AAA, 31⋅9 per cent of the patients had died.
The risk of death was significantly associated with age, co-morbidity, social deprivation and geographical region (Table S2 , supporting information). Adjusted Kaplan-Meier curves demonstrated a better 5-year survival rate in patients receiving statins (68⋅4 versus 42⋅2 per cent), antiplatelet agents (63⋅6 versus 39⋅7 per cent) or antihypertensive agents (61⋅5 versus 39⋅1 per cent) than in those not receiving each treatment (Fig. 3) .
Intervention with medications
Using the G-computation formula, the use of statins for patients with AAA was associated with a 20 per cent lower risk of death (hazard ratio (HR) 0⋅80, 95 per cent c.i. 0⋅77 to 0⋅83) ( Fig. 4; Table S3 , supporting information). The inclusion of non-statin LMT was associated with a slightly greater benefit than statins alone (HR 0⋅79, 0⋅76 to 0⋅82). Compared with no therapy, current practice was associated with a 26 per cent lower risk of death (HR 0⋅74, 0⋅71 to 0⋅77). No antihypertensives Antihypertensives Fig. 3 Weighted adjusted Kaplan-Meier curves of survival after diagnosis of abdominal aortic aneurysm (AAA) with and without a statin, b antiplatelet and c antihypertensive therapy. a-c P < 0⋅001 (univariable Cox models using inverse probability)
Antiplatelet agents were associated with a 20 per cent lower risk of death than when no patient received antiplatelets (HR 0⋅80, 95 per cent c.i. 0⋅77 to 0⋅83). Current practice was associated with 11 per cent fewer deaths than if no patient had received antiplatelet drugs (HR 0⋅89, 0⋅86 to 0⋅92). The use of anticoagulants was also associated with improved survival (all receiving anticoagulants versus current practice: HR 0⋅96, 0⋅92 to 1⋅00; all versus none receiving anticoagulants: HR 0⋅85, 0⋅82 to 0⋅88).
Prescription of ACE inhibitors, ARBs and CCBs was associated with better survival (HR 0⋅79, 95 per cent c.i. 0⋅76 to 0⋅82; HR 0⋅67, 0⋅65 to 0⋅70; HR 0⋅85, 0⋅82 to 0⋅88 respectively) ( Fig. 4; Table S3 , supporting information). A smaller benefit was seen with beta-blockers (HR 0⋅94, 0⋅91 to 0⋅98). In contrast, no benefit was observed with diuretic prescriptions (HR 1⋅18, 1⋅14 to 1⋅22). Overall, any single antihypertensive agent was associated with 12 per cent fewer deaths than when no antihypertensive agent was prescribed (HR 0⋅88, 0⋅85 to 0⋅92), although the use of antihypertensive agents for all patients did not improve survival compared with current clinical practice (HR 0⋅97, 0⋅93 to 1⋅01).
Discussion
The major finding of this study was that, although medications to mitigate cardiovascular risk are associated with a clinically and statistically significant improvement in long-term survival in patients with an AAA, the proportion of these individuals receiving such medications remains quite poor in the UK. The data suggest that only 76⋅7 per cent were on statins, 73⋅9 per cent were taking antiplatelet agents and 84⋅0 per cent antihypertensive medication by 2012, with evidence of considerable geographical variation. There was improvement in the rate of prescription of CVD-modifying medications during the study, and long-term survival improved in these patients. Overall life expectancy was better than in large studies of patients after AAA repair 18 , reflecting the fact that the cohort for this study included patients with a small AAA below the threshold for surgical repair. The interventions associated with greatest clinical benefit were statins and antiplatelet agents. Ensuring the universal use of these medications could save an additional 62 lives per 1000 patients per year, with the greatest benefit being derived from statins and LMT. Antiplatelet agents and statins are recommended for patients with an AAA 10 , and this study confirms the benefit on long-term survival. Patients with AAA have a substantial burden of baseline CVD and associated risk factors, and a reduced life expectancy compared with that in the general population. The present study demonstrates that this risk may be modifiable 5 through the use of therapeutic interventions known to reduce CVD risk. This study highlights the importance of the cardiovascular risk associated with AAA, and the need for greater attention to risk management.
The benefit of statin therapy in preventing vascular events in patients with pre-existing CVD has been established in large-scale pooled analyses of RCTs 7, 19 . In addition, patients deemed to be at relatively low risk of future CVD events have also been shown to derive benefit from statin therapy 20, 21 .
The benefit of aspirin treatment for the secondary prevention of CVD has also been confirmed through similar meta-analyses of clinical trials 22 ; aspirin treatment has been recommended as a class I indication in the joint American Heart Association-American College of Cardiology Foundation guidelines 23 . Likewise, antihypertensive medications have also been recommended as a class I indication for the secondary prevention of CVD events 23 . It is known from previous studies that incremental levels of both systolic and diastolic BP are log-linearly associated with the risk of vascular events 24 . As the majority of individuals with AAA have co-existing hypertension, optimized BP control is likely to reduce the risk of future vascular events. The observation that ACE inhibitors, ARBs and CCBs have mortality benefits whereas beta-blockers/diuretics have a lesser impact is in keeping with many clinical guidelines, which advocate these as first-and second-line treatments for hypertension; beta-blockers have been relegated to fourth line 25 . Based on the present findings, it can be concluded that addressing treatment gaps (for CVD and its risk factors) in patients with AAA may improve their long-term survival. The findings of this study merit interpretation in the context of its limitations, especially those that relate to the quality and completeness of the available data. For instance, details regarding AAA morphology and size, factors that are known to predict long-term survival, were not available for analysis in the THIN data set. Medications were considered to be current in patients for the 90 days that followed a prescription, but patients' compliance with therapy was not known. Furthermore, the data set had information on all-cause mortality rather than cardiovascular death.
Although not all patients will be able to tolerate some of these risk-reducing medications, this study demonstrates that there is potential room for improvement in their prescription in general practice. Many of these patients will also have been seen by a vascular surgeon in secondary care, where there is the opportunity to ensure maximum use of these medications.
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